Last reviewed · How we verify

NCT06216964: DECHLAGO

Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study

Recruiting now NA Last updated 3 August 2025
What this trial tests

NA trial testing Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) NAAT(s) in Chlamydia Trachomatis in 140 participants. Currently enrolling.

Timeline
5 April 2024
Primary endpoint
1 November 2027
1 November 2027

Quick facts

Lead sponsorUniversity Hospital, Strasbourg, France
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment140
Start date5 April 2024
Primary completion1 November 2027
Estimated completion1 November 2027
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Strasbourg, France

Who can join

18 and older, any sex, with Chlamydia Trachomatis or Neisseria Gonorrhoeae. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the negativation time of chlamydial and gonococcal PCRs after treatment for urogenital, oropharyngeal and anal infections.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chlamydia Trachomatis

Currently open trials in the same condition.

Other University Hospital, Strasbourg, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06216964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing